Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED30 (functional) | > 10000 nM | Agonistic activity of the compound was evaluated by HL-60 cell differentiation activity; Not detectable | ChEMBL. | 11354380 |
ED30 (functional) | > 10000 nM | Agonistic activity of the compound was evaluated by HL-60 cell differentiation activity; Not detectable | ChEMBL. | 11354380 |
IC50 (functional) | = 17 nM | Antagonistic activity of the compound was evaluated in terms of inhibition of HL-60 cell differentiation activity by ATRA (10 nM) | ChEMBL. | 11354380 |
IC50 (functional) | = 17 nM | Antagonistic activity of the compound was evaluated in terms of inhibition of HL-60 cell differentiation activity by ATRA (10 nM) | ChEMBL. | 11354380 |
Relative EC30 (binding) | = 2.5 | Retinoid activity of the compound at Retinoic acid receptor alpha was evaluated relative to that of All-trans retinoic acids(Mean of ATRA EC50 = 1.06 nM) | ChEMBL. | 11354380 |
Relative EC30 (binding) | = 22 | Retinoid activity of the compound at Retinoic acid receptor beta was evaluated relative to that of All-trans retinoic acids(Mean of ATRA EC50 = 1.02 nM) | ChEMBL. | 11354380 |
Relative EC30 (binding) | = 180 | Retinoid activity of the compound at Retinoic acid receptor gamma was evaluated relative to that of All-trans retinoic acids(Mean of ATRA EC50 = 0.26 nM) | ChEMBL. | 11354380 |
Relative EC30 (binding) | = 2.5 | Retinoid activity of the compound at Retinoic acid receptor alpha was evaluated relative to that of All-trans retinoic acids(Mean of ATRA EC50 = 1.06 nM) | ChEMBL. | 11354380 |
Relative EC30 (binding) | = 22 | Retinoid activity of the compound at Retinoic acid receptor beta was evaluated relative to that of All-trans retinoic acids(Mean of ATRA EC50 = 1.02 nM) | ChEMBL. | 11354380 |
Relative EC30 (binding) | = 180 | Retinoid activity of the compound at Retinoic acid receptor gamma was evaluated relative to that of All-trans retinoic acids(Mean of ATRA EC50 = 0.26 nM) | ChEMBL. | 11354380 |
Relative IC50 (binding) | = 0.7 | In vitro binding affinity of the compound towards Retinoic acid receptor alpha evaluated relative to that of All-trans retinoic acids(Mean of ATRA IC50 = 0.66 nM) | ChEMBL. | 11354380 |
Relative IC50 (binding) | = 22 | In vitro binding affinity of the compound towards Retinoic acid receptor gamma evaluated relative to that of All-trans retinoic acids(Mean of ATRA IC50 = 0.42 nM) | ChEMBL. | 11354380 |
Relative IC50 (binding) | = 32 | In vitro binding affinity of the compound towards Retinoic acid receptor beta evaluated relative to that of All-trans retinoic acids(Mean of ATRA IC50 = 0.52 nM) | ChEMBL. | 11354380 |
Relative IC50 (binding) | = 0.7 | In vitro binding affinity of the compound towards Retinoic acid receptor alpha evaluated relative to that of All-trans retinoic acids(Mean of ATRA IC50 = 0.66 nM) | ChEMBL. | 11354380 |
Relative IC50 (binding) | = 22 | In vitro binding affinity of the compound towards Retinoic acid receptor gamma evaluated relative to that of All-trans retinoic acids(Mean of ATRA IC50 = 0.42 nM) | ChEMBL. | 11354380 |
Relative IC50 (binding) | = 32 | In vitro binding affinity of the compound towards Retinoic acid receptor beta evaluated relative to that of All-trans retinoic acids(Mean of ATRA IC50 = 0.52 nM) | ChEMBL. | 11354380 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 11354380 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.